Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Filed with HKEX · Stock code 9966 · · 12 pages · English
Summary by 6ix AI
It reports on the movements in authorized and registered share capital, confirming a total at the end of the month. The document also includes details on issued shares, treasury shares, and public float sufficiency confirmation. Additionally, it outlines the movements in issued shares and treasury shares, including share repurchases during the month.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Alphamab Oncology
- Next Day Disclosure Return
- 2026 Interim report
- 2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
- 2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
- Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
Later from Alphamab Oncology
All Alphamab Oncology news releasesFollow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology